衰弱表型的结局特异性阈值与临床相关变化:基于人群的纵向队列研究
该研究在≥65岁社区人群中评估衰弱评分与不良结局的剂量反应关系,确定致残、住院和死亡的结局特异性阈值及严重程度分级,并计算最小临床重要差异。结果显示FTS和FTS-5可区分不同风险轨迹,衰弱评分降低与住院和死亡风险下降相关。
要点
- FTS致残风险阈值为25/100,FTS-5为10/50;住院阈值分别为40/100和15/50;死亡阈值分别为50/100和25/50。
- 衰弱评分增加与所有结局风险升高相关,评分降低对住院和死亡有保护作用。
- FTS和FTS-5可克服传统工具在定义风险轨迹和监测变化方面的局限。
核心结论
- FTS和FTS-5具有结局特异性阈值和严重程度分级,适用于临床评估衰弱风险轨迹和监测变化。
研究设计与样本
- 前瞻性社区居住≥65岁人群队列,基线(Wave 1)和5.02年后(Wave 2)用FTS(n=1811)和FTS-5(n=1597)评估衰弱。
主要发现
- 衰弱评分与所有结局呈连续剂量反应关系,具有不同阈值、斜率和饱和点。
- 致残风险阈值为25/100 FTS(FTS-5为10/50),住院为40/100(15/50),死亡为50/100(25/50)。
- 根据风险顺序和强度定义了五个严重程度类别。
- MCID分析显示衰弱评分增加与所有结局风险升高相关,评分降低对住院和死亡有保护作用。
关键数值与推荐
- 致残风险阈值:FTS 25/100或FTS-5 10/50;住院风险阈值:FTS 40/100或FTS-5 15/50;死亡风险阈值:FTS 50/100或FTS-5 25/50。
- FTS降低≥10.3分与住院风险降低相关(HR 0.74,95%CI 0.56-0.99);FTS-5降低≥6.5分(HR 0.74,95%CI 0.55-0.996)。
- FTS降低≥4.5分与死亡风险降低相关(HR 0.65,95%CI 0.45-0.95);FTS-5降低≥1.0分(HR 0.65,95%CI 0.45-0.93)。
临床怎么用
- 可使用FTS或FTS-5的结局特异性阈值识别不同风险等级的衰弱老年人。
- 监测衰弱评分变化,评分降低达到MCID提示住院和死亡风险下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The usefulness of assessing Frailty Phenotype is hampered by the limitations of classical tools in defining outcome-specific risk trajectories, stablishing its severity, monitoring longitudinal changes and quantifying the changes needed to modify the risk. OBJECTIVE: To assess the risk along the score range, defining outcome-specific thresholds, slopes of risk and degrees of severity and to determine Minimal Clinically Important Differences (MCIDs) through numerical-score based tools: Frailty Trait Scale (FTS). DESIGN, SETTING AND SUBJECTS: Prospective community-dwelling cohort of people ≥65 years. METHODS: Frailty was determined at baseline (Wave 1) and after 5.02 years (Wave 2) using the FTS (n = 1811) and its shorter 5-items form (FTS-5; n = 1597). Primary outcomes assessed at Wave 2 were worsening disability (median follow-up 5.02 years), hospitalisation (3.3) and mortality (5.4). For MCIDs analyses, time-to-event outcomes assessed at Wave 3 were 2.99, 4.18 and 6.77 years, respectively. Cox proportional hazards models and logistic regression were used. RESULTS: A continuous dose-response association was observed between frailty scores and all outcomes, with distinct thresholds, slopes and saturation points. Threshold for disability risk was 25/100 FTS (or 10/50 for FTS5); 40/100 (15/50 FTS5) for hospitalisation and 50/100 (25/50 FTS5) for mortality. The sequence and intensity of these risks allowed to define five different categories of severity. MCID analyses showed increases in frailty scores associated with higher risk of all outcomes, whereas reductions protected against hospitalisation [FTS ≥ 10.3: HR 0.74 (95% CI, 0.56-0.99); FTS5 ≥ 6.5: 0.74 (0.55-0.996)] and mortality [FTS ≥ 4.5: HR 0.65 (95% CI, 0.45-0.95); FTS5 ≥ 1.0: 0.65 (0.45-0.93)]. CONCLUSIONS: Both FTS and FTS5 show characteristics that make them useful in clinical settings, overcoming some of the pitfalls of classical tools.
引用
- Álvarez-Bustos A, Carnicero JA, García-Aguirre M, et al. Outcome-specific thresholds and clinically relevant changes in frailty: evidence from a population-based longitudinal cohort. Age Ageing. 2026. PMID: 42735387. doi:10.1093/ageing/afag272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。